Trophos SA

Trophos SA, is a clinical stage pharmaceutical company developing innovative therapeutics for indications with under-served needs in neurology and cardiology.

The Company has a novel and proprietary cholesterol-oxime based chemistry platform generating a pipeline of drug candidates that enhance the function and survival of stressed cells via modulation of dysfunctional mitochondria through interactions at the permeability transition pore (mPTP).

Recently published clinical studies support the therapeutic rationale for mitochondria targeted drugs in neurology (Alzheimer’s disease) and cardiology (ischemia-reperfusion injury). Trophos is uniquely placed to exploit this validated therapeutic approach with its proprietary chemistry platform targeting the mitochondrial pore.